3 Essential Benefits of Intelligent CPQ for Chemicals & Process Companies

March 14, 2018

In a diverse and demanding marketplace with many product classes and customer scenarios to consider, sales teams in today’s complex chemicals and process businesses are constantly juggling variables that can potentially slow the sales process. Sales effectiveness is a major lever for chemicals and process companies. Download this whitepaper to learn how a modern CPQ solution can mobilize your proposal process for velocity and efficiency.

Spotlight

Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in im

OTHER WHITEPAPERS
news image

Silicone-Base Coating Mitigates Corrosion Under Insulation (CUI) In Petrochemical Plants

whitePaper | June 15, 2021

Corrosion under insulation (CUI) is one of the costliest problems in the petrochemical industry. It also presents a high degree of potential danger. CUI occurs when moisture mixed with contaminants infiltrates insulation, encouraging the development of corrosion cells on the steel underneath. This paper demonstrates how Sherwin-Williams Heat-Flex® High-Temp 1200 withstands temperature fluctuations, thermal shock and other upset conditions to protect against hidden CUI.

Read More
news image

Trends policy responses and the role of internationalco-operation and trade

whitePaper | January 16, 2022

This paper is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and the arguments employed herein do not necessarily reflect the official views of OECD member countries.

Read More
news image

Industrial Internet of Things for hazardous areas: potential for the optimisation of existing plants

whitePaper | February 11, 2020

Whether oil and gas, chemicals, pharmaceuticals, mining or food, the development of an Industrial Internet of Things (IIoT) in combination with algorithms and artificial intelligence, releases an enormous optimisation potential - also and especially for existing plants. New business models transform CAPEX into OPEX and reduce the financial risk. For this, however, the information chain consisting of individual IIoT modules must not only be stringent,

Read More
news image

Lithium batteries whitepaper

whitePaper | December 25, 2022

Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Read More
news image

Modelling of Environmental Ageing of Polymers and Polymer Composites Modular and Multiscale Methods

whitePaper | January 5, 2022

Service lifetimes of polymers and polymer composites are impacted by environmental ageing.

Read More
news image

We create chemistry for a sustainable future

whitePaper | March 24, 2023

This presentation contains forward-looking statements. These statements are based on current estimates and projections of the Board of Executive Directors and currently available information. Forward-looking statements are not guarantees of the future developments and results outlined therein.

Read More

Spotlight

Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in im

Events